TrialBlood advances2026
Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study.
Noa G Holtzman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
TrialBlood advances2026
Noa G Holtzman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.